Suppr超能文献

治疗前列腺腺癌的患者,在治疗后至少随访 10 年,年龄小于 60 岁,采用近距离放射治疗的长期结果和毒性。

Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up.

机构信息

Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA.

出版信息

Urology. 2013 Feb;81(2):364-8. doi: 10.1016/j.urology.2012.08.112.

Abstract

OBJECTIVE

To report the outcomes and late toxicities in younger patients with long-term follow-up treated with brachytherapy with or without external beam radiotherapy for prostate adenocarcinoma.

MATERIALS AND METHODS

Patients treated with brachytherapy with or without external beam radiotherapy who were aged ≤ 60 years at treatment with ≥ 10 years of follow-up were selected from our database. The outcomes were analyzed regarding biochemical failure, distant metastases, and cause of death. Genitourinary outcomes were assessed using the International Prostate Symptom Score, Radiation Therapy Oncology Group, and Common Terminology Criteria for Adverse Events criteria. Gastrointestinal toxicity was measured using Radiation Therapy Oncology Group scales. Erectile dysfunction was measured using Sexual Health Inventory for Men and the Mount Sinai Erectile Function score.

RESULTS

A total of 131 patients met the inclusion criteria, with a median age of 57 years at treatment and a median follow-up of 11.5 years. Of the patients in this cohort, 9.9% developed biochemical failure with 1 failure and 1 prostate cancer-related death after 10 years. The International Prostate Symptom Score were statistically unchanged after 10 years. Of 22 cases (17%) of grade 2 or greater genitourinary toxicities, only 6 (4.5%) continued after 10 years. Of 11 cases (8.3%) of grade 2 or greater gastrointestinal events, none persisted past 10 years. A significant decrease occurred in the mean Sexual Health Inventory for Men score from 19.5 to 15.3 (P = .008). Of the potent patients before treatment, 69% remained potent at last follow-up. A total of 4 second malignancies were detected, 2 of which were within the radiation field.

CONCLUSION

Men <60 years old who underwent brachytherapy for prostate cancer can expect minimal late genitourinary and gastrointestinal toxicity after 10 years and excellent potency preservation.

摘要

目的

报告在接受近距离放射治疗联合或不联合外部束放射治疗的年轻(年龄≤60 岁)且随访时间≥10 年的前列腺腺癌患者中的结果和晚期毒性。

材料和方法

从我们的数据库中选择了接受近距离放射治疗联合或不联合外部束放射治疗且治疗时年龄≤60 岁且随访时间≥10 年的患者。分析了生化失败、远处转移和死亡原因的结果。采用国际前列腺症状评分(International Prostate Symptom Score)、放射治疗肿瘤学组(Radiation Therapy Oncology Group)和不良事件通用术语标准(Common Terminology Criteria for Adverse Events)评估泌尿生殖系统结局。采用放射治疗肿瘤学组量表评估胃肠道毒性。采用男性健康调查量表(Sexual Health Inventory for Men)和西奈山勃起功能评分(Mount Sinai Erectile Function score)评估勃起功能障碍。

结果

共有 131 例患者符合纳入标准,中位治疗年龄为 57 岁,中位随访时间为 11.5 年。在该队列中,9.9%的患者发生生化失败,10 年后有 1 例生化失败和 1 例前列腺癌相关死亡。10 年后国际前列腺症状评分无统计学变化。22 例(17%)患者出现 2 级或更高级别的泌尿生殖系统毒性,仅 6 例(4.5%)在 10 年后持续存在。11 例(8.3%)患者出现 2 级或更高级别的胃肠道事件,无 1 例持续 10 年以上。男性健康调查量表的平均评分从 19.5 分显著下降至 15.3 分(P=.008)。治疗前勃起功能正常的患者中,69%在最后一次随访时仍保持勃起功能。共发现 4 例第二恶性肿瘤,其中 2 例位于放射野内。

结论

接受近距离放射治疗的年龄<60 岁的前列腺癌患者,在 10 年后可能会出现轻微的晚期泌尿生殖系统和胃肠道毒性,并且保持良好的勃起功能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验